# Cevostamab

Source: https://onco.cc/drugs/cevostamab/  
OnCo record `cevostamab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cevostamab is an experimental investigational agent whose form is not stated in the registry from Hoffmann-La Roche in phase 3 trials for multiple myeloma, with its target not yet stated publicly.

## Summary

Cevostamab is an investigational agent whose form is not stated in the registry developed by Hoffmann-La Roche. The sponsor describes its target as FcRH5, which OnCo does not yet have a target page for. ClinicalTrials.gov describes the intervention as: Participants will receive cevostamab IV as per the schedule given in the protocol. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07555938 (Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma), in multiple myeloma. The largest, NCT07555938, plans to enrol 380 participants with primary completion expected 2028-10-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: antibody (INN stem -mab; form not stated in the registry record)
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of Cevostamab: https://clinicaltrials.gov/search?intr=Cevostamab

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)
- trials: [A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multi](https://onco.cc/trials/nct05535244/), [A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma](https://onco.cc/trials/nct05583617/), [Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma](https://onco.cc/trials/nct07555938/)
- targets: [FcRH5 (FCRL5)](https://onco.cc/targets/fcrh5/)
- biomarkers: [FcRH5 expression](https://onco.cc/biomarkers/fcrh5-expression/)

---
JSON: https://onco.cc/api/v1/entities/cevostamab.json